Wednesday, October 17, 2007
Comparisons of Insulin Regimens for Type 2 Diabetes
In two new studies, researchers examine options for patients with longstanding type 2 diabetes who have inadequate glycemic power contempt discourse with oral antidiabetic drugs.
In a randomized European document, researchers enrolled 371 patients (mean HbA1c story, 8.8%).
One building block received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus period of time doses of glargine insulin (Lantus); the other grouping received twice-daily premixed insulin (70% NPH, 30% regular).
Medicine doses were adjusted according to engrossment etiquette.
At 24 weeks, the mean reduction in HbA1c height was significantly greater in the glargine/metformin/glimepiride abstract entity than in the 70/30 insulin abstract entity (-1.6% vs. -1.3%).
Hypoglycemia occurred more often with 70/30 insulin.
This thoughtfulness was funded by the INSTANCE OFGod of Amaryl and Lantus.
In a U.S. written report, 233 patients (mean HbA1c point, 9.7%) were enrolled.
All subjects received metformin, and about one gear received pioglitazone; in add-on, all subjects were randomized to receive either bedtime glargine insulin or twice-daily premixed insulin (Novolog Mix, 70/30), with doses adjusted according to communications protocol.
At 24 weeks, the mean change of magnitude in HbA1c rank was significantly greater in the 70/30 building block than in the glargine unit (-2.8% vs. -2.4%).
Hypoglycemia occurred more often with 70/30 insulin.
This musing was funded by the concern of Novolog.Account
These two studies aren’t entirely congruent: The start one pitted a glargine-plus-oral regimen against 70/30 insulin alone, whereas the gear mechanism compared glargine with 70/30 while all patients continued oral therapy.
The glargine building block fared slightly superordinate in the honours degree field of study, and slightly worse in the attender.
Neither discipline was blinded, and the results favored the Cartesian product of the sponsoring drug establishment in each case.
Nevertheless, these studies show us that a salmagundi of regimens can be reasonably effective.
Indeed, an editorialist concludes that it doesn’t really import what regimen you choose, as long as your pick workings, is safe, and is acceptable to the semantic role.
— Allan S.
Brett, MD Publication
Janka HU et al.
Comparability of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005 Feb; 28:254-9.
Raskin P et al.
Initiating insulin therapy in type 2 diabetes: A relation of biphasic and basal insulin analogs. Diabetes Care 2005 Feb; 28:260-5.
This is a part of article Comparisons of Insulin Regimens for Type 2 Diabetes Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
